Related Experiment Videos
Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections
1Department of General Surgery, City Hospital of Leverkusen, Germany.
Abstract:
Intra-abdominal infections are a serious problem for surgeons. Treatment consists of a combination of operation, antimicrobial treatment, and supportive measures. beta-Lactam antibiotics have a major role in the treatment of peritonitis, and in combination with beta-lactamase inhibitors, the penicillins have an even larger part to play than previously. A multicentre prospective trial to evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of serious intra-abdominal infections was conducted in Europe. One hundred and six evaluable patients with documented intra-abdominal infections were treated with piperacillin 4 g/tazobactam 500 mg every eight hours. The most common diagnoses were peritonitis, intra-abdominal abscess, and complicated diverticulitis. A 90% favourable clinical response rate (cured/improved) was found during the first two weeks of treatment. Piperacillin/tazobactam was extremely active against the Gram-negative aerobic, Gram-positive aerobic, and anaerobic bacteria isolated in this trial. Overall, the drug was well tolerated and the side effects were minimal.
Insights
Piperacillin/tazobactam effectively treats serious intra-abdominal infections, showing a 90% clinical response rate. This antibiotic combination was well-tolerated with minimal side effects in a European trial.
Area of Science:
- Infectious Diseases
- Surgical Infections
- Pharmacology
Background:
- Intra-abdominal infections pose significant surgical challenges.
- Effective treatment relies on surgery, antimicrobials, and supportive care.
- Beta-lactamase inhibitors enhance penicillin efficacy against resistant bacteria.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin/tazobactam.
- To assess treatment outcomes in patients with serious intra-abdominal infections.
- To analyze the antimicrobial spectrum of piperacillin/tazobactam in a clinical setting.
Main Methods:
- A multicenter prospective trial conducted in Europe.
- 106 evaluable patients with documented intra-abdominal infections were enrolled.
- Treatment involved piperacillin 4 g/tazobactam 500 mg administered every eight hours.
Main Results:
- A 90% favorable clinical response rate (cured/improved) was observed within two weeks.
- Piperacillin/tazobactam demonstrated high activity against Gram-negative, Gram-positive, and anaerobic bacteria.
- The drug was well-tolerated, with minimal reported side effects.
Conclusions:
- Piperacillin/tazobactam is an effective and safe treatment option for serious intra-abdominal infections.
- The combination therapy shows broad-spectrum activity against common pathogens.
- This regimen offers a valuable therapeutic choice for surgical infections.